Pietro Annovazzi
A5001026935- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Polyomavirus and related diseases
- Reproductive System and Pregnancy
- Immunotherapy and Immune Responses
- Acute Lymphoblastic Leukemia research
- Systemic Sclerosis and Related Diseases
- Rheumatoid Arthritis Research and Therapies
- Pregnancy and Medication Impact
- Migraine and Headache Studies
- Sphingolipid Metabolism and Signaling
- Cytokine Signaling Pathways and Interactions
- SARS-CoV-2 and COVID-19 Research
- Systemic Lupus Erythematosus Research
- T-cell and B-cell Immunology
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Trigeminal Neuralgia and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Bacterial Infections and Vaccines
- Fungal Plant Pathogen Control
- Long-Term Effects of COVID-19
- Immune Cell Function and Interaction
- Psoriasis: Treatment and Pathogenesis
- Stroke Rehabilitation and Recovery
- Hereditary Neurological Disorders
Azienda Socio Sanitaria Territoriale della Valle Olona
2020-2025
Multiple Sclerosis Foundation
2017-2024
Azienda Ospedaliera Sant’Antonio Abate di Gallarate
2010-2024
Associazione Italiana Sclerosi Multipla
2009-2023
King's College London
2022
Guy's and St Thomas' NHS Foundation Trust
2022
Evelina London Children's Healthcare
2022
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2022
University of Genoa
2009-2020
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2019
To assess fetal risk after pregnancy exposure to natalizumab in women with multiple sclerosis (MS), a specific focus on spontaneous abortion (SA) and congenital anomalies (CA).Data of all pregnancies occurring between 2009 2015 patients MS treated referring 19 participating sites were collected compared those untreated injectable immunomodulatory agents. Rates SA CA also reported the Italian population. Multivariable logistic linear regression models performed.A total 92 tracked 83 women. In...
It is unclear how multiple sclerosis (MS) affects the severity of COVID-19. The aim this study to compare COVID-19-related outcomes collected in an Italian cohort patients with MS expected age- and sex-matched population.Hospitalization, intensive care unit (ICU) admission, death after COVID-19 diagnosis 1,362 were compared population a retrospective observational case-cohort population-based control. observed vs events whole different subgroups (higher risk: Expanded Disability Status Scale...
<h3>Background and Objectives</h3> We sought to identify early factors associated with relapse outcome in paediatric-onset myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD). <h3>Methods</h3> In a multicenter retrospective cohort of pediatric MOGAD (≤18 years), onset features treatment were compared patients monophasic vs relapsing disease (including cases follow-up ≥12 months after or at any time) final Expanded Disability Status Scale (EDSS) 0 ≥1 last >3 event...
Background: Patients with multiple sclerosis (pwMS) treated anti-CD20 or fingolimod showed a reduced humoral response to SARS-CoV-2 vaccines. Objective: In this study we aimed monitor the risk of breakthrough infection in pwMS on different disease-modifying therapies (DMTs). Methods: Data number vaccinated patients and were retrospectively collected 27 Italian MS centers. We estimated rate infections requiring hospitalization per DMT. Results: 19,641 included database. After median follow-up...
The aim of the present study is to assess actual and lifetime frequency neuropathic (trigeminal neuralgia, L'Hermitte's sign, dysesthesic pain) somatic (painful muscle spasms low back pain headache (tensive migraine) in a cross-sectional sample 428 consecutive multiple sclerosis (MS) outpatients followed-up an Italian University MS center over 3-month period. impact demographic disease-related variables on risk also studied. A semi-structured questionnaire was administered during...
<h3>Objective:</h3> To analyze changes in T-helper (Th) subsets, T-regulatory (Treg) cell percentages and function, mRNA levels of immunologically relevant molecules during a 24-month follow-up after alemtuzumab treatment patients with relapsing-remitting multiple sclerosis (RRMS). <h3>Methods:</h3> Multicenter 29 alemtuzumab-treated RRMS the Comparison Alemtuzumab Rebif Efficacy Multiple Sclerosis (CARE-MS) I CARE-MS II trials. Peripheral blood (PB) samples were obtained at months 0, 6, 12,...
Background: Natalizumab and fingolimod have not been compared in controlled trials but only observational studies, with inconclusive results. Objectives: The objective of this study is to compare the effect natalizumab reducing disease activity relapsing-remitting multiple sclerosis (RRMS). Methods: We included all consecutive RRMS patients switched from first-line agents (glatiramer acetate/interferons) or fingolimod, a follow-up 24 months. Data relapses, Expanded Disability Status Scale...
Introduction: With the spread of SARS-CoV2 pandemic, telemedicine has become safest way to guarantee care continuity, especially for chronic disabling diseases requiring frequent medical consultations and therapeutic adjustments, such as Parkinson's disease (PD). The age-related prevalence PD, combined with increased vulnerability due comorbidities, makes PD patients protection a priority.
There is debate as to whether the apparent rebound after fingolimod discontinuation related itself or it due natural course of highly active multiple sclerosis (MS). Our aim was survey prevalence severe reactivation and in a cohort Italian patients with MS.Patients relapsing-remitting MS who were treated for at least 6 months stopped treatment reasons that unrelated inefficacy included analysis.A total 100 had discontinued study. Fourteen (14%) relapse within 3 discontinuation, an additional...
<h3>Objective</h3> To assess the risk of disease reactivation during pregnancy after natalizumab suspension in women with multiple sclerosis (MS). <h3>Methods</h3> Data all pregnancies occurring between 2009 and 2015 patients MS treated referring to 19 participating sites were collected compared those untreated injectable immunomodulatory agents through a 2-factor repeated measures analysis. Predictors activity assessed stepwise multivariable logistic regression models. <h3>Results</h3> A...
The exclusion of other diseases that can mimic multiple sclerosis (MS) is the cornerstone current diagnostic criteria. However, data on frequency MS mimics in real life are incomplete.A total 695 patients presenting with symptoms suggestive any 22 RIREMS centers underwent a detailed workup, including brain and spinal cord MRI scan, CSF blood examinations, 3-year clinical radiologic follow-up.A 667 completed study. Alternative diagnoses were formulated 163 (24.4%) cases, most frequent being...
The MuSC-19 project is an Italian cohort study open to international partners that collects data on multiple sclerosis (MS) patients with COVID-19. During the second wave of pandemic, serological tests became routinely available.To evaluate seroprevalence anti-SARS-CoV-2 antibodies according use disease-modifying therapy (DMT) in a subset included set who had undergone test.We evaluated association between positive test results and time elapsed since infection onset, age, sex, Expanded...
<b>Objective:</b> To compare the efficacy, tolerability, and safety of IV methylprednisolone (IV MP) vs oral (oMP) at equivalent high doses in patients with multiple sclerosis (MS) experiencing a recent relapse. <b>Methods:</b> Patients clinical relapse within previous 2 weeks least 1 gadolinium (Gd)-enhancing lesion on screening brain MRI scan were included. Forty MS randomized to receive either g/day for 5 days oMP (20 patients) or MP patients). Expanded Disability Status Scale (EDSS)...
To assess whether the presence of concomitant diseases at multiple sclerosis (MS) diagnosis is associated with choice and treatment persistence in an Italian MS cohort.We included newly diagnosed patients (2010-2016) followed 20 centers collected demographic clinical data. We evaluated baseline factors related to comorbidities association between course time first switch.The study cohort 2,076 patients. Data on were available for 1,877/2,076 (90.4%). A total 449/1,877 (23.9%) had least 1...
In MS, discontinuation of some therapies may result in a transitory, possibly overwhelming, increase disease activity.1–4 We report 2 cases severe clinical rebound after fingolimod suspension occurring patients following pregnancy. Clinical was defined as the occurrence new neurologic symptoms together with significant or enlarging T2-weighted gadolinium-enhancing T1-weighted lesions exceeding baseline activity, on treatment discontinuation.4 The first patient diagnosed MS 2005. subsequent 3...
To study the effect of natural menopause on multiple sclerosis clinical course.This was an observational, retrospective, multicentre, cohort study. Menopause onset defined by final menstrual period (FMP) beyond which no menses occurred for 12 months. We included (MS) patients with FMP after 2005 and a recorded follow-up at least 2 years pre-FMP post-FMP. excluded primary progressive course, iatrogenic other confounders that could mask onset. compared relapse-rate expanded disability status...
Background: With many options now available, first therapy choice is challenging in multiple sclerosis (MS) and depends mainly on neurologist patient preferences. Objectives: To identify prognostic factors for early switch after choice. Methods: Newly diagnosed relapsing–remitting MS patients from 24 Italian centers were included. We evaluated the association of baseline demographics, clinical, magnetic resonance imaging (MRI) data to probability lack efficacy or intolerance/safety with a...